By vgreene, 29 June, 2020 Study considerations: retrospective; treatment bias; TCZ group w/ sicker pts and higher rate of steroid tx; limited f/u
By vgreene, 29 June, 2020 Composite primary outcome: mech vent rate similar w/ TCZ vs SOC (18% vs 16%) but death rate lower w/ TCZ (7% vs 20%); TCZ assoc w/ reduced mech vent or death risk in adjusted analysis (adjusted HR 0.61, 95% CI 0.4-0.92); more new infxns w/ TCZ vs SOC (13%
By vgreene, 29 June, 2020 Retrospective, multicenter, cohort study; 544 pts (median age 67y) w/ severe COVID-19 received TCZ (8 mg/kg IV q12h x2 doses, max 800 mg/dose, or 162 mg SC x2 doses) + SOC (n=179) or SOC alone (n=365); SOC incl. HCQ +/- AZ, LPV/r, or DRV/c, and LMWH for D
By vgreene, 29 June, 2020 Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO 19 Randomized Clinical Trial
By vgreene, 29 June, 2020 Study considerations: randomized but open-label; small sample size; inconclusive results based on limited data and analysis